Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT

International Journal of Pharmaceutics

Volumn 396, Issue 1-2, 2010, Pages 111-118

  Zheng, Xiaowan ^a   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Bile acid transporter; Ketoprofen; MDCK cells; Niacin; Prolonged release; Stability

Indexed keywords

APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER; BILE ACID CONJUGATE; CARRIER PROTEIN; CHENODEOXYCHOLIC ACID; KETOPROFEN; LYSINE; NICOTINIC ACID; PRODRUG; UNCLASSIFIED DRUG; COTRANSPORTER; DELAYED RELEASE FORMULATION; DRUG CARRIER; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER; TAUROCHOLIC ACID;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG POTENCY; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; IN VITRO STUDY; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION; ANALOGS AND DERIVATIVES; ANIMAL; CACO 2 CELL LINE; DELAYED RELEASE FORMULATION; DOG; DRUG FORMULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; HYDROLYSIS; KINETICS; LIVER; MEDICINAL CHEMISTRY; METABOLISM; PHARMACEUTICS; PROCEDURES; RAT; SOLUBILITY; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; CHENODEOXYCHOLIC ACID; DELAYED-ACTION PREPARATIONS; DOGS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; HUMANS; HYDROLYSIS; KETOPROFEN; KINETICS; LIVER; LYSINE; NIACIN; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PRODRUGS; RATS; SOLUBILITY; SYMPORTERS; TAUROCHOLIC ACID; TECHNOLOGY, PHARMACEUTICAL; TRANSFECTION;

EID: 77955052974     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.06.039     Document Type: Article

References (45)

1. Alrefai W.A., Gill R.K. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 2007, 24:1803-1823.
2. Balakrishnan A., Hussainzada N., Gonzalez P., Bermejo M., Swaan P.W., Polli J.E. Bias in estimation of transporter kinetic parameters from overexpression systems: interplay of transporter expression level and substrate affinity. J. Pharmacol. Exp. Ther. 2007, 320:133-144.
3. Balakrishnan A., Polli J.E. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol. Pharm. 2006, 3:223-230.
4. Balakrishnan A., Sussman D.J., Polli J.E. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm. Res. 2005, 22:1269-1280.
5. Balakrishnan A., Wring S.A., Coop A., Polli J.E. Influence of charge and steric bulk in the C-24 region on the interaction of bile acids with human apical sodium-dependent bile acid transporter. Mol. Pharm. 2006, 3:282-292.
6. Balakrishnan A., Wring S.A., Polli J.E. Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation. Pharm. Res. 2006, 23:1451-1459.
7. Balimane P.V., Tamai I., Guo A., Nakanishi T., Kitada H., Leibach F.H., Tsuji A., Sinko P.J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 1998, 250:246-251.
8. Benyo Z., Gille A., Kero J., Csiky M., Suchankova M.C., Nusing R.M., Moers A., Pfeffer K., Offermanns S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest. 2005, 115:3634-3640.
9. Burnette T.C., de M.P. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab. Dispos. 1994, 22:60-64.
10. Cordi A., Lacoste J.M., Duhault J., Espinal J., Boulanger M., Broux O., Husson B., Volland J.P., Mahieu J.P. Synthesis of 1,2-diacyl-3-nicotinoyl glycerol derivatives and evaluation of their acute effects on plasma lipids in the rat. Arzneimittelforschung 1995, 45:997-1001.
11. Dawson P.A., Haywood J., Craddock A.L., Wilson M., Tietjen M., Kluckman K., Maeda N., Parks J.S. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. 2003, 278:33920-33927.
12. Dawson P.A., Lan T., Rao A. Bile acid transporters. J. Lipid Res. 2009.
13. Dawson P.A., Oelkers P. Bile acid transporters. Curr. Opin. Lipidol. 1995, 6:109-114.
14. Filip C., Ungureanu D., Gheorghita N., Ghitler N., Mocanu G., Nechifor M. Hypolipidemic effect of a prodrug containing nicotinic acid in rats. Correlation with plasmatic levels. Rev. Med. Chir. Soc. Med. Nat. Iasi 2003, 107:179-183.
15. Gallop, M.A., Cundy, K.C. Bile-acid conjugates for providing sustained systemic concentrations for drugs. PCT/US01/42628. 11-4-2002a. WO 02/28883 A1. 9-10-2001a. Ref. type: Patent.
16. Gallop, M.A., Cundy, K.C. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration. PCT/US01/42513. 11-4-2002b. WO 02/28881 A1 Ref. type: Patent.
17. Gonzalez E.L., Patrignani P., Tacconelli S., Rodriguez L.A. Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 2010.
18. Gonzalez P., Polli J.E. Impact of impurity on kinetic estimates from transport and inhibition studies. J. Pharmacol. Exp. Ther. 2008, 326:296-305.
19. Han H., de Vrueh R.L., Rhie J.K., Covitz K.M., Smith P.L., Lee C.P., Oh D.M., Sadee W., Amidon G.L. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 1998, 15:1154-1159.
20. Kantor T.G. Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy 1986, 6:93-103.
21. Knopp R.H., Alagona P., Davidson M., Goldberg A.C., Kafonek S.D., Kashyap M., Sprecher D., Superko H.R., Jenkins S., Marcovina S. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097-1104.
22. Kramer W., Wess G. Bile acid transport systems as pharmaceutical targets. Eur. J. Clin. Invest. 1996, 26:715-732.
23. Kramer W., Wess G., Enhsen A., Bock K., Falk E., Hoffmann A., Neckermann G., Gantz D., Schulz S., Nickau L. Bile acid derived HMG-CoA reductase inhibitors. Biochim. Biophys. Acta 1994, 1227:137-154.
24. Kramer W., Wess G., Schubert G., Bickel M., Girbig F., Gutjahr U., Kowalewski S., Baringhaus K.H., Enhsen A., Glombik H. Liver-specific drug targeting by coupling to bile acids. J. Biol. Chem. 1992, 267:18598-18604.
25. Larsen C., Jensen B.H., Olesen H.P. Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. Acta Pharm. Nord. 1991, 3:71-76.
26. Menon R.M., Gonzalez M.A., Adams M.H., Tolbert D.S., Leu J.H., Cefali E.A. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J. Clin. Pharmacol. 2007, 47:681-688.
27. Montagnani M., Love M.W., Rossel P., Dawson P.A., Qvist P. Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand. J. Gastroenterol. 2001, 36:1077-1080.
28. Morgan J.M., Capuzzi D.M., Guyton J.R. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am. J. Cardiol. 1998, 82:29U-34U.
29. Oelkers P., Kirby L.C., Heubi J.E., Dawson P.A. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J. Clin. Invest. 1997, 99:1880-1887.
30. Petzinger E., Nickau L., Horz J.A., Schulz S., Wess G., Enhsen A., Falk E., Baringhaus K.H., Glombik H., Hoffmann A. Hepatobiliary transport of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids. Hepatology 1995, 22:1801-1811.
31. Petzinger E., Wickboldt A., Pagels P., Starke D., Kramer W. Hepatobiliary transport of bile acid amino acid, bile acid peptide, and bile acid oligonucleotide conjugates in rats. Hepatology 1999, 30:1257-1268.
32. Pieper J.A. Understanding niacin formulations. Am. J. Manag. Care 2002, 8:S308-S314.
33. Pieper J.A. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am. J. Health Syst. Pharm. 2003, 60:S9-14.
34. Piepho R.W. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am. J. Cardiol. 2000, 86:35L-40L.
35. Pike N.B. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J. Clin. Invest. 2005, 115:3400-3403.
36. Porter R.S., Kaplan L.J. The Merck Manuals Online Medical Library 2009, Merck Research Laboratories, Division of Merck & Co., Inc., Whitehouse Station, NJ.
37. Rais R., Gonzalez P.M., Zheng X., Wring S.A., Polli J.E. Method to screen substrates of apical sodium-dependent bile acid transporter. AAPS J. 2008, 10:596-605.
38. St-Pierre M.V., Kullak-Ublick G.A., Hagenbuch B., Meier P.J. Transport of bile acids in hepatic and non-hepatic tissues. J. Exp. Biol. 2001, 204:1673-1686.
39. Stern R.H., Freeman D., Spence J.D. Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action?. Metabolism 1992, 41:879-881.
40. Tantishaiyakul V., Wiwattanawongsa K., Pinsuwan S., Kasiwong S., Phadoongsombut N., Kaewnopparat S., Kaewnopparat N., Rojanasakul Y. Characterization of mefenamic acid-guaiacol ester: stability and transport across Caco-2 cell monolayers. Pharm. Res. 2002, 19:1013-1018.
41. Tolle-Sander S., Lentz K.A., Maeda D.Y., Coop A., Polli J.E. Increased acyclovir oral bioavailability via a bile acid conjugate. Mol. Pharm. 2004, 1:40-48.
42. Wang L.F., Chiang H.N., Wu P.C. Kinetics and hydrolysis mechanism of polymeric prodrugs containing ibuprofen, ketoprofen, and naproxen as pendent agents. J. Biomater. Sci. Polym. Ed. 2002, 13:287-299.
43. Wong M.H., Oelkers P., Dawson P.A. Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity. J. Biol. Chem. 1995, 270:27228-27234.
44. Wong M.H., Rao P.N., Pettenati M.J., Dawson P.A. Localization of the ileal sodium-bile acid cotransporter gene (SLC10A2) to human chromosome 13q33. Genomics 1996, 33:538-540.
45. Zheng X., Ekins S., Raufman J.P., Polli J.E. Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol. Pharm. 2009, 6:1591-1603.